CA
NZ
UK
AU
IND
US
Shares of Royalty Pharma (Nasdaq:RPRX) closed at $58.43, down 1.00% on the day and roughly $2 below the 52-week high of $60.44. The move itself is noise. The timing is not: the company reports second-quarter results before the US open on Wednesday 5 August, …
Co. (NYSE:MRK). Shares of Merck & Co. closed at $130.20 at last closing, three sessions after touching a 52-week high of $131.84 on 27 July. The company reports second-quarter results on the morning of 4 August, with a call at 9:00 a.m. ET.
Mettler-Toledo (NYSE:MTD) filed its second-quarter results with the SEC after the close on 30 July, and they did something the precision-instrument sector has managed only fitfully since laboratory capex budgets tightened: beat and raise together. Net sales of $1.027 billion rose 4% as reported …
Natera (Nasdaq:NTRA) enters August 2026 with the widest gap in years between its operating momentum and its share price. The cell-free DNA testing company closed at $267.76, down 0.7% on the session and about 7% below the $288.04 52-week high, according to aggregated market …
Neurocrine Biosciences (Nasdaq:NBIX) posted second-quarter 2026 revenue of $959.0 million, up 39% from $687.5 million a year earlier, with GAAP diluted earnings of $1.39 a share and non-GAAP diluted earnings of $2.85. Management raised full-year Ingrezza guidance. The market's verdict arrived the following session: …
Madrigal Pharmaceuticals (Nasdaq:MDGL) published second-quarter results at last closing that cleared Wall Street's bar on both lines. Rezdiffra, resmetirom, the thyroid hormone receptor-beta agonist that in March 2024 became the first therapy the FDA approved for MASH with liver fibrosis, booked $364.3 million in …
Medline (Nasdaq:MDLN) publishes second-quarter 2026 results before the open on Wednesday 5 August, with a call at 9:30 a.m. ET. It is only the company's third report as a public business, and it arrives with the investment case pulling in two directions.
Medtronic (NYSE:MDT) closed its acquisition of SPR Therapeutics, paying $650 million in cash upfront for a private company whose lead product does something unusual in neuromodulation: it leaves nothing behind. SPR's SPRINT system delivers 60 days of peripheral nerve stimulation through a fine lead …
Insmed (Nasdaq:INSM) closed at $98.60, down 2.85% on the day and lower for a sixth consecutive session, according to aggregated market data. That leaves the Bridgewater, New Jersey company valued at about $21.4bn, still one of the largest US commercial-stage biotechs without a profit, …
Insulet Corporation (Nasdaq:PODD) reports second-quarter results with an unusually wide gap between its operating numbers and its share price. The maker of Omnipod, the tubeless patch pump taking share from tubed insulin pumps and injection therapy alike, grew first-quarter revenue 33.9% and lifted full-year …
Please wait processing your request...